Craneware plc (LSE:CRW), the Edinburgh-based software group whose revenue-integrity and 340B pharmacy tools are used by roughly 40% of US hospitals, has had an uncomfortable summer. On 3 July 2026 the AIM-quoted company warned that Revenue and adjusted EBITDA for the year to 30 June 2026 would be flat rather than growing, and 17 days later it disclosed a cyber-security incident. The shares, at 1,320p on 2 September, sit near the bottom of a 52-week range of 1,082p to 2,600p, giving a Market Capitalisation of about £452m.
Full-year results are due this month, and the central question is whether the slippage in 340B and enterprise contract revenue is a timing problem, as management insists, or a sign of a tougher market.
Trading update: flat FY26 as 340B conversion stalls, then a cyber breach
The 3 July trading update told investors to expect FY26 revenue of $205m to $208m and adjusted EBITDA of $65m to $67m, against $205.7m and $65.3m in FY25. Given that the first half had delivered 6% revenue growth and 10% adjusted EBITDA growth, the guidance implies a weaker second half and a miss against prior market expectations.
Two factors were blamed. First, the pace at which identified 340B opportunities converted into eligible drug purchases, on which Craneware's related revenue depends, "slowed significantly as pharmaceutical manufacturers further expanded and operationalised restrictions". Roughly $500m of outstanding qualifying drug purchases have yet to convert. Second, a small number of significant enterprise contracts moved from FY26 into FY27.
Chief executive Keith Neilson said that "while short-term pharmacy market complexity impacted the year, the long-term opportunity remains intact", describing the group as "expanding beyond software and analytics into technology-enabled operational transformation". Three days later he bought 9,074 shares at 1,102p, worth £99,999, taking his holding to 9.42% of the company.
On 20 July Craneware then reported unauthorised access to part of its data environment. A significant Volume of file names was viewed and exfiltrated, including some employee data and customer and partner records, though much was described as non-sensitive regulatory information. The incident was contained, external specialists found no residual indicators of compromise, and customer services were not disrupted. The UK Information Commissioner's Office and the FBI were notified. Sharecast reported the shares fell 6.75% to 1,132p that day.
What Craneware does
Craneware sells cloud-based financial and operational software to US hospitals and health systems, and reports in US dollars. Its Trisus platform combines revenue-integrity products such as Trisus Chargemaster, which helps hospitals price and bill services accurately, with cost management, analytics and pharmacy solutions. The July 2021 acquisitions of Sentry Data Systems and Agilum Healthcare added 340B programme management and medication analytics.
The 340B scheme lets eligible US hospitals buy outpatient drugs at discounted prices; Craneware's software identifies and administers qualifying purchases, so its income there depends on how many purchases actually go through. The customer base is sticky: retention exceeds 90%, and the top ten customers account for 30% of revenue with average relationships of more than 20 years. Growth comes chiefly from selling additional Trisus modules into that base, which generated 88% of new sales in the first half of FY26. A Microsoft Partnership has put 13 Trisus solutions on the Azure Marketplace and produced Trisus Assist, an AI assistant used by more than 200 customers.
Financial performance: record FY25, solid first half, then the stall
FY25, the year to 30 June 2025, was a record. Revenue rose 9% to $205.7m, annual Recurring Revenue grew 7% to $184.0m with net revenue retention of 107%, and adjusted EBITDA increased 12% to $65.3m, a 32% margin. Operating profit was $25.3m against $19.7m, profit before tax rose 52% to $24.0m and adjusted basic EPS climbed 22.5% to 116.1 cents. Cash stood at $55.9m against bank Debt of $27.7m, cash conversion was 94% of adjusted EBITDA, and the total Dividend rose 10% to 32.0p. A $100m unsecured revolving Credit facility, with a $100m accordion, was agreed in September 2025.
The six months to 31 December 2025 continued the trend. Revenue rose 6% to $105.7m, adjusted EBITDA 10% to $33.4m, operating profit 22% to $13.3m and profit before tax 29% to $13.0m. Adjusted basic EPS was 58.7 cents and basic EPS 28.6 cents. ARR reached $184.2m, up 4%, with net revenue retention of 103%. Cash was $40.9m plus $30.3m in transit, bank debt had fallen to $23.4m, the Interim Dividend rose to 15.0p from 13.5p and the board signalled a $25m share buyback. The July update means the second half will have reversed much of that momentum, at least at the top line.
What could drive the stock next
The most immediate catalyst is the FY26 results announcement, expected in September 2026 (last year's arrived on 15 September). Investors will look for final numbers within the guided ranges, year-end ARR and net revenue retention, the FY27 outlook and any update on the buyback. Confirmation that the deferred enterprise contracts have since been signed would support the "timing" explanation.
The $500m of unconverted 340B qualifying purchases is the biggest swing factor. Craneware said in March it had delivered the only enterprise-grade integrated solution for the pilot 340B rebate model, so any easing of manufacturer restrictions or clarity on the pilot could unlock deferred revenue. New AI products launched around HIMSS26, covering labour productivity and reimbursement intelligence, plus the Azure Marketplace channel, offer incremental growth, and the chair has said the Balance Sheet allows the board to review M&A opportunities.
Risks investors should watch
The 340B market is the obvious risk. Pharmaceutical manufacturers have been tightening restrictions on discounted supply, and the shift to a rebate model changes how the programme operates; further restrictions could keep conversion slow beyond FY26. Enterprise deals that slipped into FY27 could slip again or shrink.
The cyber incident is not yet closed. Notification, regulatory, litigation and remediation costs were not quantified, and reputational damage matters for a company that handles hospital financial data. Customer concentration adds sensitivity, with 30% of revenue from ten clients. Craneware reports in dollars but pays sterling dividends and trades in pence, so currency moves affect returns. Finally, the shares have roughly halved from their 52-week high, and a second downgrade would test investor patience even with a near-10% Shareholder in the chief executive's seat.
Outlook
Craneware enters results season with a profitable, cash-generative and largely recurring business, net cash and a chief executive who has bought shares at lower prices. Against that stand a guided flat year, an unresolved cyber investigation and a 340B market the company does not control. The September results, the FY27 outlook and evidence that the $500m purchase Backlog is converting will show whether the summer setbacks are a pause or a turning point.






Please wait processing your request...